AI Science Tracker

AlphaGenome

3 discoveries name this family, 2025 to 2026

Where AlphaGenome appears in the catalog

Why linked?

These associations match family names in discovery titles and technology text. They are not verified model-version assignments or causal attribution. Missing links do not establish absence of use. A record may link to multiple families.

Represented fields

biology · 3 linked records

Test contexts

retrospective or benchmark · 3 linked records

Annotation coverage

Evidence annotation present · 3 linked records

Examples

Up to three linked records, newest publication date first, then stable ID. This selection is not a ranking.

Discoveries

Paper2Agent integrates perturbation datasets to prioritize GPR137 at a psoriasis risk locus

Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data. A cross-screen correlation of gene-expression signatures supported GPR137 as the probable causal gene under stimulated conditions (Spearman rho 0.613 at 8 h and 0.630 at 48 h; FDR < 0.05), but not at rest. The paper presents this as activation-dependent computational evidence.

Technology: Paper2Agent-generated AlphaGenome, MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq agents, coordinated through an AI co-scientist

Family AI Co-Scientist: profile · models page

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data.
  • Still unknown: The analysis reuses existing published datasets and does not report new wet-lab experiments for this psoriasis case. AlphaGenome supplied a model prediction; cross-dataset signature correlation supports, but does not establish, causal biology. The GPR137 concordance was significant only after stimulation, and the authors describe it as probable/activation-dependent. A human researcher selected which AI-proposed strategy to run. Primary paper source checked; no independent replication assessed.
  • AI role: The AlphaGenome paper agent scored and ranked candidate genes at rs887314. Under human-in-the-loop supervision, the AI co-scientist inspected two other paper agents' datasets, proposed ten validation strategies, and the researcher selected signature-correlation analysis. The resulting cross-screen, cross-modality analysis found significant concordance for GPR137 only under stimulated conditions.

Evidence sources: https://www.nature.com/articles/s41586-026-11044-y

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Google DeepMind

AlphaGenome Atlas: predictive map of human DNA variation

A precomputed database of predicted molecular effects for about 9 billion possible single-letter changes in the human genome, generated by AlphaGenome. Researchers can access it free through a portal and API. The predictions are a research tool, do not replace experiments, and are not validated for clinical use.

Technology: AlphaGenome, AlphaGenome Variant Impact (AVI)

Family AlphaGenome: profile · models page

Publication: Announcement only · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Announcement only
  • Test type: retrospective or benchmark
  • Tested: Validation described is the company's own testing of the AlphaGenome Variant Impact score on pathogenicity benchmarks, plus case studies: a DNM1 variant prioritized with GREGoR and 22% more non-coding associations in UK Biobank.
  • Still unknown: The page does not detail how individual predictions were checked; AlphaGenome is not validated or approved for clinical use.
  • AI role: AlphaGenome predicted variant effects across cell types and tissues; these were precomputed for about 9 billion variants and combined with AlphaMissense into a single score.

Evidence sources: https://deepmind.google/blog/alphagenome-atlas-a-predictive-map-of-every-possible-dna-letter-change-in-the-human-genome/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Google DeepMind

AlphaGenome: predicting the effects of DNA variants

The model reads sequences up to 1 million base pairs and predicts thousands of gene-regulation properties at single-letter resolution. It outperformed the best external models in 22 of 24 sequence evaluations and matched or outperformed the best in 24 of 26 variant evaluations. Stated limits: distant regulatory elements; not validated for personal genomes or clinical use.

Technology: AlphaGenome

Family AlphaGenome: profile · models page

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: AlphaGenome was evaluated on sequence and variant-effect benchmarks against external models, outperforming in 22 of 24 and matching or exceeding in 24 of 26 evaluations, plus a TAL1 case study.
  • Still unknown: The source states it is not validated for personal genomes or clinical use, distant regulatory elements remain a challenge, and cell-specific patterns need improvement.
  • AI role: A model takes up to 1 million DNA base pairs and predicts thousands of genomic tracks and variant effects.

Evidence sources: https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome/ · https://www.biorxiv.org/content/10.1101/2025.06.25.661532

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.